| |
|
HE | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 25. | The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial |
| |
Ann Intern Med. 2021 Feb 2. doi: 10.7326/M20-0202. Online ahead of print.
Christophe Bureau 1, Dominique Thabut 2, Caroline Jezequel 3, Isabelle Archambeaud 4, Louis D'Alteroche 5, Sêbastien Dharancy 6, Patrick Borentain 7, Frédéric Oberti 8, Aurélie Plessier 9, Victor De Ledinghen 10, Nathalie Ganne-Carrié 11, Nicolas Carbonell 12, Vanessa Rousseau 13, Agnès Sommet 13, Jean Marie Péron 1, Jean Pierre Vinel 1
|
|
| |
|
|
| |
|
|
| |
| 28. | North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension |
| |
Clin Gastroenterol Hepatol. 2021 Jul 15;S1542-3565(21)00749-7.doi: 10.1016/j.cgh.2021.07.018. Online ahead of print.
Justin R Boike 1, Bartley G Thornburg 2, Sumeet K Asrani 3, Michael B Fallon 4, Brett E Fortune 5, Manhal J Izzy 6, Elizabeth C Verna 7, Juan G Abraldes 8, Andrew S Allegretti 9, Jasmohan S Bajaj 10, Scott W Biggins 11, Michael D Darcy 12, Maryjane A Farr 13, Khashayar Farsad 14, Guadalupe Garcia-Tsao 15, Shelley A Hall 16, Caroline C Jadlowiec 17, Michael J Krowka 18, Jeanne Laberge 19, Edward W Lee 20, David C Mulligan 21, Mitra K Nadim 22, Patrick G Northup 23, Riad Salem 2, Joseph J Shatzel 24, Cathryn J Shaw 25, Douglas A Simonetto 26, Jonathan Susman 27, K Pallav Kolli 19, Lisa B VanWagner 28, Advancing Liver Therapeutic Approaches (ALTA) Consortium
|
|
| |
|
|
| |
| 30. | Sleep and liver disease: a bidirectional relationship |
| |
Lancet Gastroenterol Hepatol. 2021 Jul 14;S2468-1253(21)00169-2.doi: 10.1016/S2468-1253(21)00169-2. Online ahead of print.
Thomas Marjot 1, David W Ray 2, Felicity R Williams 3, Jeremy W Tomlinson 2, Matthew J Armstrong 4
|
|
| |
|
|
| |
|
|
| |
| 33. | Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial) |
| |
BMJ Open Gastroenterol. 2020 Dec;7(1):e000531. doi: 10.1136/bmjgast-2020-000531.
K de Wit 1, J J Schaapman 2, F Nevens 3, J Verbeek 3, S Coenen 4, F J C Cuperus 5, M Kramer 6, E T T L Tjwa 7, N Mostafavi 8, M G W Dijkgraaf 9, O M van Delden 10, U H W Beuers 1, M J Coenraad 2, R B Takkenberg 11
|
|
| |
| 34. | The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis |
| |
J Hepatol. 2020 Dec 7;S0168-8278(20)33836-8. doi: 10.1016/j.jhep.2020.11.048.Online ahead of print.
Vicente Arroyo 1, Paolo Angeli 2, Richard Moreau 3, Rajiv Jalan 4, Joan Claria 5, Jonel Trebicka 6, Javier Fernández 5, Thierry Gustot 7, Paolo Caraceni 8, Mauro Bernardi 8, investigators from the EASL-CLIF Consortium, Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EFClif)
|
|
| |
|
|
| |
| 36. | The use of Rifaximin in Patients with Cirrhosis |
| |
Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708. Online ahead of print.
Paolo Caraceni 1, Victor Vargas 2, Elsa Solà 3, Carlo Alessandria 4, Koos de Wit 5, Jonel Trebicka 6 7, Paolo Angeli 8, Rajeshwar P Mookerjee 9, François Durand 10, Elisa Pose 3, Aleksander Krag 11 12, Jasmohan S Bajaj 13, Ulrich Beuers 5, Pere Ginès 3
|
|
| |
|
|
| |
|
| |
|
|
|
|
|
